← All stocks

Rapport Therapeutics, Inc.

RAPP Net buying
CIK 0002012593 #1932 in the set updated 17 Sep 2026
Bought (120 mo)
$12.35M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$50.10M
$49.42M on a plan · $342.14K straight out of an exercise
Sold at will
$340.94K
3 of 84 sales
Net
−$37.75M
+$12.01M against sales at will

By person

11 insiders · 109 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Third Rock Ventures V, L.P. entity
10% owner
$34.39M (5) scheduled
−$34.39M
7,249,743
15.11%
$333.59M
+1,142%
HEALY JAMES
Director
$10.58M (17)
+$10.58M
40,851
0.0851%
$1.88M
Ceesay Abraham
Chief Executive Officer
$7.99M (38) scheduled
−$7.99M
582,164
1.21%
$26.79M
−28.2%
Yeleswaram Krishnaswamy
Chief Development Officer
$4.46M (11) scheduled
−$4.46M
195,862
0.4082%
$9.01M
−32.7%
Bredt David
Chief Scientific Officer
$2.16M (21) scheduled
−$2.16M
393,075
0.8193%
$18.09M
−23.5%
Gault Cheryl
Chief Operating Officer
$1.10M (9) scheduled
−$1.10M
149,914
0.3125%
$6.90M
−5.1%
PAUL STEVEN M
Director
$1.03M (2)
+$1.03M
41,666
0.0868%
$1.92M
Huber Reid M
Director
$499.37K (1)
+$499.37K
20,400
0.0425%
$938.70K
Young Wendy B.
Director
$140.35K (2)
+$140.35K
9,500
0.0198%
$437.14K
Ignelzi Troy A.
Chief Financial Officer
$100.99K (2)
+$100.99K
10,000
0.0208%
$460.15K
ARCH Venture Partners XII, LLC entity
10% owner
3,728,738
7.77%
$171.58M
Insider
Date
Role
Action
Shares
Price
Amount
Gault Cheryl
5 Mar 2026
Chief Operating Officer
Sell
2,014
$28.93
$58.27K
Yeleswaram Krishnaswamy
31 Dec 2025
Chief Development Officer
Sell
2,840
$30.05
$85.34K
Bredt David
31 Dec 2025
Chief Scientific Officer
Sell
6,567
$30.05
$197.34K

What was left out

Form 4 filings counted 89
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 79
Sales straight out of an exercise 2
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 12,699,130
History held since 10 Jun 2024